Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 4/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | ATR | Q13535 | 6/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29835147 | 0.85 | CYP4F2 (0.39) | S1PR3CYP4F2CYP4A11RXRARXRB | |
| SCHEMBL24934378 | 0.78 | ATR (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21835567 | 0.76 | CD274 (0.39) | S1PR1S1PR3CYP4F2CYP4A11RXRA | |
| SCHEMBL22824029 | 0.75 | CYP4F2 (0.38) | RETCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL15244570 | 0.74 | RXRA (0.38) | RETCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL21187505 | 0.74 | GAA (0.43) | RETCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30429840 | 0.73 | RET (0.36) | RETCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30430129 | 0.73 | RET (0.37) | RETCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL31467472 | 0.73 | BAZ2B (0.34) | RAB9A | |
| SCHEMBL21185044 | 0.72 | RET (0.50) | RETCYP4F2CYP4A11RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | S1PR1 3479/4885S1PR3 3907/4885RET 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.